Synertec Corporation Limited (ASX: SOP) today announced further details of its $45.5 million engineering services contract, revealing the Australian Nuclear Science and Technology Organisation (ANSTO) as the client. Synertec Corporation Ltd is a technology design and development growth company enabling a low carbon future through innovative technology solutions, commercialising scalable, environmentally friendly and energy efficient technology for global markets. Synertec will serve as the Process Design and Design Integration lead for ANSTO’s next-generation Nuclear Medicine Manufacturing Facility at Lucas Heights, New South Wales, a project critical for enhancing Australia’s sovereign nuclear medicine manufacturing capability.
The extensive scope of services for the $45.5 million contract, spanning approximately eight years, includes process architecture and engineering design, specialised GMP and radiological manufacturing systems, systems engineering, requirements and interface management, facility-wide design integration, regulatory support, and commissioning support. Financially, approximately $36 million in revenue is anticipated to be recognised during the initial 26-month design phase, which commences on 21 September 2026. The project is poised for robust financial performance, with the contribution margin expected to exceed 25% and gross margin on labour at the upper end of Synertec’s target range. Furthermore, it is projected to remain cumulatively cash-flow positive for more than 90% of its term, requiring minimal working capital.
The appointment strategically positions Synertec within ANSTO’s critical Nuclear Medicine Manufacturing Program, aimed at replacing existing radiopharmaceutical production infrastructure. This award validates Synertec’s industry diversification and geographic expansion, strengthening its presence in the nuclear and healthcare sectors, and accelerating New South Wales operations. Synertec’s Managing Director, Michael Carroll, expressed delight, noting the project reflects the company’s capability in highly regulated engineering environments. A favourable impact on FY27 revenue guidance is anticipated, with further updates planned as execution details become more certain.
